|
0
|
|
Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.
(linkinghub.elsevier.com)
|
Blakney AK
…
Sadarangani M
The Lancet
2026-06-30
|
#vaccination
#rna
#immunogenicity
#safety
#pharmacovigilance
|
|
0
|
|
Enhanced B cell priming induces broadly neutralizing HIV-1 apex antibodies.
(nature.com)
|
Marchitto L
…
Shaw GM
Nature
2026-06-30
|
#immunity
#antibody
#hiv
#vaccination
#immunogenicity
|
|
0
|
|
Efficacy of WRSs2, a live-attenuated Shigella sonnei vaccine, against shigellosis in a controlled human infection model in the USA: a phase 2, double-blind, randomised, placebo-controlled trial.
(linkinghub.elsevier.com)
|
Rouphael N
…
Frenck RW Jr
Lancet Infectious Diseases
2026-06-30
|
#vaccination
#shigellosis
#clinical trial
#live-attenuated
#immunogenicity
|
|
0
|
|
Vaccination elicits HIV broadly neutralizing antibodies in primates.
(nature.com)
|
Steichen JM
…
Schief WR
Nature
2026-06-30
|
#vaccination
#antibody
#hiv
#immunogenicity
#b cell
|
|
0
|
|
Lineage dynamics and risk factors underlying serotype 4 invasive pneumococcal disease in Spain.
(academic.oup.com)
|
Perez-Garcia C
…
Yuste J
Journal of Infectious Diseases
2026-06-30
|
#serotype
#pneumococcal
#genomics
#virulence
#vaccination
|
|
0
|
|
Efficacy, safety, and immunogenicity of an Escherichia coli-produced nine-valent human papillomavirus vaccine: a multicentre, double-blind, randomised, controlled, phase 3 trial.
(linkinghub.elsevier.com)
|
Pan HX
…
Xia NS
Lancet Infectious Diseases
2026-06-30
|
#vaccination
#immunogenicity
#hpv
#clinical trial
#cervical cancer
|